Literature DB >> 11252663

Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder.

C G Hahn1, E Friedman.   

Abstract

Protein kinase C (PKC) is a group of calcium and phospholipid-dependent enzymes, which plays a pivotal role in cell signaling systems. Recently accumulated evidence indicates that alterations in PKC activity play a significant role in the pathophysiology of bipolar disorder. A number of laboratories investigated the effect of mood stabilizers on the regulation of PKC activity in bipolar patients, in animals, and in cultured cells. Following chronic lithium treatment, PKC activation was significantly reduced in rat brains, as measured by the translocation of cytoplasmic PKC to the membrane compartment, or by quantitative binding of the PKC ligand, PDBu. The effect of the therapeutic concentration of lithium in attenuating PKC-dependent intracellular parameters was also demonstrated in cultured cells. More importantly, alterations in platelet PKC was shown in bipolar patients during the manic state of the illness. In comparison to patients with major depressive disorder, schizophrenia, or healthy controls, PKC activity was significantly increased in manic patients, suggesting that changes in PKC may be an illness-specific marker. Interestingly, enhanced PKC activity during mania was suppressed following mood-stabilizer treatment as manic symptoms improved. In parallel to the findings in platelets, postmortem studies demonstrate that membrane-associated PKC and stimulation-induced translocation of cytosolic enzyme to the membrane were also increased in frontal cortex of bipolar patients. Other studies suggest alterations in other signal transduction mechanisms in bipolar disorder. These include alterations in G protein activation, phosphatidylinositol (PI) signaling, cyclic AMP formation, and intracellular calcium homeostasis. The alterations of PKC activity in bipolar disorder may be related to changes in these other intracellular signaling mechanisms. Alternatively, the changes of PKC activity may be the core pathology of the illness. More studies are required to further characterize the association of PKC changes with bipolar disorder, using a proper neuronal model.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11252663     DOI: 10.1034/j.1399-5618.1999.010204.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  38 in total

Review 1.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

2.  The underlying neurobiology of bipolar disorder.

Authors:  Husseini K Manji; Jorge A Quiroz; Jennifer L Payne; Jaskaran Singh; Barbara P Lopes; Jenilee S Viegas; Carlos A Zarate
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

3.  Fluvastatin inhibits Rab5-mediated IKs internalization caused by chronic Ca2+-dependent PKC activation.

Authors:  Xiaorong Xu Parks; Elsa Ronzier; Jin O-Uchi; Coeli M Lopes
Journal:  J Mol Cell Cardiol       Date:  2019-03-18       Impact factor: 5.000

Review 4.  Tamoxifen use for the management of mania: a review of current preclinical evidence.

Authors:  Fernanda Armani; Monica Levy Andersen; José Carlos Fernandes Galduróz
Journal:  Psychopharmacology (Berl)       Date:  2014-01-18       Impact factor: 4.530

Review 5.  Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics.

Authors:  Rosilla F Bachmann; Robert J Schloesser; Todd D Gould; Husseini K Manji
Journal:  Mol Neurobiol       Date:  2005-10       Impact factor: 5.590

6.  Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania.

Authors:  Steven T Szabo; Rodrigo Machado-Vieira; Peixiong Yuan; Yun Wang; Yanling Wei; Cynthia Falke; Chiara Cirelli; Giulio Tononi; Husseini K Manji; Jing Du
Journal:  Neuropharmacology       Date:  2008-08-22       Impact factor: 5.250

Review 7.  Potential mechanisms of action of lithium in bipolar disorder. Current understanding.

Authors:  Gin S Malhi; Michelle Tanious; Pritha Das; Carissa M Coulston; Michael Berk
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

Review 8.  Bipolar disorder: candidate drug targets.

Authors:  Carlos A Zarate; Husseini K Manji
Journal:  Mt Sinai J Med       Date:  2008 May-Jun

Review 9.  The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis.

Authors:  Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Bipolar Disord       Date:  2009-06       Impact factor: 6.744

10.  Pathway analysis of GWAS provides new insights into genetic susceptibility to 3 inflammatory diseases.

Authors:  Hariklia Eleftherohorinou; Victoria Wright; Clive Hoggart; Anna-Liisa Hartikainen; Marjo-Riitta Jarvelin; David Balding; Lachlan Coin; Michael Levin
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.